Liver Cancer Trials

Study Title

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Principal Investigators

Study Number

RTOG-1112-Liver

Status of Trial

Open

Why is this study being done?

The standard treatment for hepatocellular carcinoma that is unsuitable for surgery or regional therapy is sorafenib, an oral drug that has been shown to increase the survival of patients compared to no active treatment.

Stereotactic body radiation therapy (SBRT), referring to the use of focused high dose radiation generally delivered in 5 or fewer treatment sessions, has also been used to treat hepatocellular carcinoma and has led to tumor shrinkage in many patients.

The purpose of this study is to compare the effects of sorafenib alone (the present standard of care treatment) with SBRT followed by sorafenib on you and your liver cancer to find out which is better. In this study, you will get either SBRT followed by sorafenib or the sorafenib alone.

Contact

Arla Yost, MSc, CCRP
Email: Arla.Yost@ucsf.edu
Phone: 415-514-9603